Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 128M | 2158.4% |
Gross Profit | 109M | 876.6% |
Cost of Revenue | 19M | 3.3% |
Operating expense | 60M | 8.4% |
Net Income | 70M | 243.3% |
EBITDA | 69M | 240.4% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 322M | 24.7% |
Total Liabilities | 225M | 3.5% |
Total Equity | 96M | 295% |
Shares Outstanding | 1.53B | 0.1% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | 47M | 248.4% |
Cash from investing | -740,000 | 107.5% |
Cash from financing | 25M | 16.2% |
EPS
Financial Highlights for Adaptimmune Therapeutics in Q2 '24
Adaptimmune Therapeutics reported a revenue of 128M, which is a 2158.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 109M, marking a 876.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 19M, a -3.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 60M, showing a 8.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 70M, showing a 243.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 69M, showing a 240.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Adaptimmune Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.